Search clinical trials for: Trastuzumab

Total 1149 results

Fudan University

Recruiting

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Metastatic Breast Cancer | HER2-positive Breast Cancer

China
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7 | ERBB2 Gene Amplification

United States
Hoffmann-La Roche

Completed

A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe

Healthy Volunteer

New Zealand
University Medical Center Groningen

Completed

Clinical Value of 89Zr-trastuzumab PET

Metastatic Breast Cancer

Netherlands
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Recurrent Osteosarcoma

Sarcoma

United States
Sanofi

Completed

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

Breast Neoplasms

France, Sweden, Switzerland, Belgium
Jules Bordet Institute

Completed

PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2

Carcinoma Breast Stage IV

Belgium
National Cancer Institute (NCI)

Active, not recruiting

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Malignant Solid Neoplasm

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Huihua Xiong

Not yet recruiting

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

Breast Cancer
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Advanced Breast Cancer
Sanofi

Completed

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer

United States
Hoffmann-La Roche

Terminated

A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (LISAH)

Breast Cancer

Austria
Medical University of Vienna
Daiichi Sankyo, Inc.

Completed

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases (TUXEDO-1)

Breast Cancer Stage IV

Austria
Meiji Seika Pharma Co., Ltd.
Dong-A Pharmaceutical

Completed

Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

Healthy Volunteer

Japan
Armando Santoro, MD

Terminated

Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients

NON-SMALL CELL LUNG CANCER

Italy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Metastatic Breast Cancer | Metastatic Gastric Cancer

China
Memorial Sloan Kettering Cancer Center
Novartis

Completed

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Breast Cancer

United States
Xuzhou Medical University

Unknown

Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer

Gastric Cancer

China
The University of Texas Health Science Center at...
National Cancer Institute (NCI)

Withdrawn

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Breast Cancer
Hoffmann-La Roche
Roche Pharma AG

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Metastatic Breast Cancer

Italy, Spain, Canada, United States, Belgium, France, Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
AstraZeneca
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (DG-06)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

HER2-positive Gastric Cancer
National University Hospital, Singapore
National University of Singapore

Unknown

NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

Breast Cancer | Gastric Cancer

Singapore
Anglo Celtic Cooperative Oncology Group

Completed

Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Breast Cancer

United Kingdom
Warwick Medical School

Unknown

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

Breast Cancer

United Kingdom
Comprehensive Support Project for Oncology Research

Completed

National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT] (RESPECT)

Breast Cancer

Japan
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Jules Bordet Institute
Roche Pharma AG

Active, not recruiting

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 (ZEPHIR)

HER-2 Positive Breast Cancer

Belgium, Netherlands
Byondis B.V.

Completed

First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Solid Tumors

Netherlands, Belgium, United Kingdom, Spain
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Aventis Pharmaceuticals

Terminated

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Breast Cancer

United States
Amsterdam UMC, location VUmc
AstraZeneca

Recruiting

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study (HER Image)

Breast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Cancer

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Esophagogastric Cancer

United States
Shanghai Zhongshan Hospital

Completed

Trastuzumab Based Therapy in HER2 Positive AGC

Gastric Adenocarcinoma

China
National Cancer Institute, France

Completed

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

Breast Cancer

France
MedSIR
Daiichi Sankyo, Inc.

Not yet recruiting

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (TUXEDO-4)

Breast Cancer | Metastatic Breast Cancer
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Breast Cancer
Hoffmann-La Roche

Completed

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Estonia, Hungary, Turkey, Israel, Slovakia, Bulgaria, Lithuania, Macedonia, The Former Yugoslav Republic of
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Breast Cancer

United States
Zhejiang Cancer Hospital

Recruiting

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Breast Cancer

China
Daiichi Sankyo, Inc.
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01)

Non-Small Cell Lung Cancer

United States, Spain, Japan, Netherlands, France
Northwell Health

Terminated

Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer

Neoplasm Metastasis

United States
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Completed

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Colorectal Neoplasm

United States, Spain, Japan, Italy, United Kingdom
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; First Affiliated Hospital of Zhejiang University; Sir... and other collaborators

Unknown

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Colorectal Cancer

China
Academisch Medisch Centrum - Universiteit van Amsterdam...
Roche Pharma AG

Completed

Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (TRAP)

Esophageal Carcinoma

Netherlands
European Organisation for Research and Treatment...
Hoffmann-La Roche; UNICANCER; Janssen Diagnostics, LLC; SUCCESS

Completed

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (TREAT-CTC)

Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Circulating Tumor Cells

France, Germany, Belgium, United Kingdom
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Advanced Breast Cancer

United States, Switzerland, China, France
Centre Antoine Lacassagne

Completed

Trastuzumab in Treating Women With Metastatic Breast Cancer

Breast Cancer

France
Finnish Breast Cancer Group

Completed

The Synergism Or Long Duration (SOLD) Study (SOLD)

Breast Neoplasms

Finland

Search clinical trials for: Trastuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations